Faster, More Accurate Mpox Detection: The New Era of Rapid Diagnostics
For years, the gold standard for diagnosing mpox (formerly monkeypox) has been the Polymerase Chain Reaction (PCR) test. While highly accurate, PCR often requires specialized laboratory equipment and hours, or even days, to return results. In a public health crisis, that delay can be the difference between containing a cluster and allowing a widespread outbreak.
A new wave of diagnostic innovation is changing that. From CRISPR-based “molecular scissors” to rapid point-of-care platforms, researchers and medical device companies are developing ways to detect the mpox virus faster, cheaper, and closer to the patient. These advancements aren’t just about convenience. they’re about enabling real-time clinical decisions and faster isolation of infected individuals.
The Shift Toward Point-of-Care Testing
The primary goal of current research is to move testing out of the central lab and into the clinic or field. Point-of-care (POC) testing allows healthcare providers to sample a patient and provide a diagnosis during a single visit.
One prominent example is the Xpert® Mpox assay. This platform provides automated, on-demand testing with results typically available in approximately 36 minutes. By reducing the turnaround time from days to under an hour, clinicians can begin treatment and implement infection control measures almost immediately.
Cutting-Edge Breakthroughs: CRISPR and LAMP
Beyond automated PCR, scientists are leveraging newer biochemical tools to create “rapid visual” tests—diagnostics that can be read as easily as a pregnancy test but with the precision of a lab assay.
- CRISPR-Based Detection: Researchers are using CRISPR-Cas proteins (like Cas12a and Cas12b) to act as biological search engines. When these proteins find a specific genetic sequence of the mpox virus, they trigger a signal. Recent studies, including work published in the Virology Journal, have demonstrated one-step LAMP-CRISPR assays that allow for rapid visual detection of the virus.
- Isothermal Amplification (LAMP and RAA): Traditional PCR requires “thermal cycling” (heating and cooling the sample repeatedly). New methods like Loop-mediated Isothermal Amplification (LAMP) and Recombinase Aid Amplification (RAA) work at a single, constant temperature. This eliminates the need for heavy machinery, making these tests portable enough for use in remote areas or resource-limited settings.
Why Clade-Specific Testing Matters
Mpox is not a single, uniform virus; it exists in different genetic lineages called clades. The World Health Organization (WHO) has highlighted the emergence of different clades, some of which may be more transmissible or severe than others. This makes “pan-specific” tests (which detect all mpox) useful for general diagnosis, but “clade-specific” tests essential for epidemiological tracking.
New diagnostic assays are being designed to distinguish between Clade I and Clade II (including the IIb epidemic clade). Knowing exactly which strain is circulating allows public health officials to tailor their response and helps doctors understand the likely progression of the disease in their patients.
- Speed: Testing times are dropping from days to minutes via platforms like Xpert® Mpox.
- Portability: Isothermal methods (LAMP/RAA) remove the need for bulky lab equipment.
- Precision: CRISPR technology enables high sensitivity with the possibility of visual, “yes/no” readouts.
- Specificity: New assays can now differentiate between mpox clades, aiding global surveillance.
Frequently Asked Questions
How is mpox currently diagnosed?
The most common method is a swab of a lesion (skin rash), which is then tested using a PCR assay to detect the virus’s DNA. While highly accurate, this usually requires a clinical laboratory.
Are these new rapid tests as accurate as PCR?
Many of the new molecular tests, particularly those using CRISPR and LAMP, aim for “PCR-level” sensitivity. While some rapid antigen tests (similar to COVID-19 home tests) may be less sensitive, the molecular POC tests currently being deployed are designed to maintain high accuracy while increasing speed.
When will these tests be available at local clinics?
Some platforms, such as Xpert®, are already available under specific regulatory authorizations (such as Emergency Use Authorizations in the U.S.). Other CRISPR and LAMP-based research tools are currently moving through clinical validation and regulatory approval phases.
The Path Forward
The trajectory of mpox diagnostics is clear: smaller, faster, and more accessible. As we move toward a future where a clinician can diagnose mpox in 30 minutes using a handheld device, the window for viral transmission narrows. The integration of clade-specific detection will further empower the global health community to stop outbreaks before they become pandemics, transforming mpox from a lingering threat into a manageable clinical challenge.